Back to CalculatorBack to Full Calculator

Module 9: Special Populations

PE management in pregnancy, cancer-associated VTE, chronic kidney disease, obesity, and other special clinical scenarios.

Pre-Test Prob.D-DimerSeverity (PESI)Category (A–E)Hestia CriteriaAnticoagulationDurationAdvanced RxSpecial Populations

Patient Context

mL/min
kg

Pregnancy

Source: 2026 AHA/ACC PE Guideline, Section 6 — Special Populations

Pregnancy — Key Rules

  • LMWH: Agent of choice throughout gestation (enoxaparin 1 mg/kg BID)
  • DOACs: Contraindicated — cross placenta
  • VKA: Avoid T1 (embryopathy) and near delivery (fetal bleeding)
  • Hold LMWH: ≥24h before delivery or neuraxial anesthesia
  • Restart: 6–12h vaginal / 12–24h cesarean after hemostasis
  • Anti-Xa monitoring: Peak 0.6–1.0 IU/mL (BID), 4h post-dose
Class I / Level C-LD2026 AHA/ACC PE Guideline, Section 6 — Pregnancy: LMWH throughout gestation (COR 1, LOE C-LD)
  1. 1

    LMWH (enoxaparin 1 mg/kg SC every 12 hours) is the anticoagulant of choice throughout gestation (COR 1, LOE C-LD). Dose should be adjusted as body weight increases with advancing pregnancy.

  2. 2

    DOACs (rivaroxaban, apixaban, edoxaban, dabigatran) are CONTRAINDICATED in pregnancy. They cross the placenta and have not been adequately studied in pregnancy.

  3. 3

    VKA (warfarin) should be AVOIDED in the first trimester (embryopathy risk) and near delivery (neonatal bleeding risk). May be used in the second trimester if LMWH is unavailable.

  4. 4

    Monitor anti-Xa levels for LMWH: peak 0.6–1.0 IU/mL (BID dosing) or 1.0–2.0 IU/mL (once-daily dosing), checked 4 hours post-dose. Dose adjustments are often needed due to increased renal clearance.

  5. 5

    Peridelivery management: hold LMWH ≥24 hours before planned induction or cesarean section. Do not administer LMWH within 12 hours of neuraxial anesthesia placement.

  6. 6

    Restart anticoagulation 6–12 hours after vaginal delivery or 12–24 hours after cesarean section, when surgical hemostasis is confirmed. Continue for minimum 6 weeks postpartum (minimum total duration: 3 months).

  7. 7

    Imaging: CT pulmonary angiography (CTPA) is acceptable in pregnancy when PE is suspected; radiation dose to fetus is low (~0.1 mGy). V/Q scan is an alternative with lower fetal dose. Clinical urgency should not be compromised by concerns over radiation exposure.

  8. 8

    Systemic thrombolysis: reserved for life-threatening PE (cardiac arrest or refractory E1) where maternal benefit outweighs fetal risk. Absolute contraindications apply.

IMPORTANT: This software is clinical decision support (CDS) intended for use by licensed healthcare professionals under Section 520(o)(1)(E) of the Federal Food, Drug, and Cosmetic Act. It is not intended as a medical device. All recommendations are derived from the 2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN Guideline for the Evaluation and Management of Acute Pulmonary Embolism (Circulation 2026;153:e977-e1051) and must be independently verified by the treating clinician before any clinical action. AI-generated content (including extracted data and clinical notes) is produced by large language models and may contain errors, omissions, or hallucinations — clinician review is mandatory. Patient data entered into the calculator is processed entirely in the browser; AI features process data server-side under a signed HIPAA Business Associate Agreement with no data retention. AI-HEART Lab, its affiliates, and contributors assume no liability for clinical decisions made using this tool. By using this tool, you acknowledge these limitations and accept full responsibility for clinical decisions.